| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Succinyl phosphonate trisodium salt targets α-ketoglutarate dehydrogenase (KGDHC/OGDH), an enzyme in the tricarboxylic acid (TCA) cycle, inhibiting its activity and thereby affecting mitochondrial bioenergetics and cellular metabolism.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Succinyl phosphonate trisodium salt effectively inhibits KGDHC in various tissues including muscle, brain, and human fibroblasts, and impairs the viability of cancer cells in a cell-specific metabolism-dependent manner.
|
| ln Vivo |
In vivo, Succinyl phosphonate trisodium salt has been used to study the role of KGDHC in metabolic regulation and cancer metabolism; it inhibits glutamate-induced ROS production in glutamate-stimulated cells, suggesting potential applications in studying oxidative stress and metabolic disorders.
|
| Enzyme Assay |
The in vitro enzyme assay for KGDHC inhibition involves incubating Succinyl phosphonate trisodium salt with purified or tissue-derived KGDHC enzyme, α-ketoglutarate substrate, CoA, and NAD+, measuring the production of NADH spectrophotometrically at 340 nm, with IC50 values calculated from inhibition curves.
|
| Cell Assay |
In vitro cell culture studies utilize cancer cell lines and primary cells treated with Succinyl phosphonate trisodium salt, assessing cell viability by MTT or CellTiter-Glo, cellular ATP levels by luciferase-based assays, mitochondrial respiration by Seahorse analysis, and ROS production by fluorescence-based assays.
|
| Animal Protocol |
In vivo animal experiments involve administering Succinyl phosphonate trisodium salt to tumor-bearing mice or metabolic disease models, assessing tumor growth inhibition, measuring KGDHC activity in tissues, and evaluating metabolic changes in plasma and tissues by metabolomics analysis.
|
| ADME/Pharmacokinetics |
Succinyl phosphonate trisodium salt is a water-soluble compound with molecular weight approximately 260.03 g/mol (trisodium salt); it is typically stored as a solid powder at -20°C and dissolved in aqueous buffers for in vitro and in vivo studies, with stability maintained under recommended conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for Succinyl phosphonate trisodium salt are limited; as a metabolic inhibitor, it may have dose-dependent effects on cell viability and mitochondrial function; comprehensive in vivo toxicity studies have not been extensively reported for this research compound.
|
| References |
|
| Additional Infomation |
Succinyl phosphonate trisodium salt is a research compound used as a biochemical tool for studying TCA cycle regulation, mitochondrial bioenergetics, and cancer metabolism; it has not been approved for clinical use and serves as a valuable tool for elucidating the role of KGDHC in metabolism and disease.
|
| Molecular Formula |
C4H7NAO6P
|
|---|---|
| Molecular Weight |
205.05831360817
|
| Exact Mass |
247.943
|
| CAS # |
864167-45-3
|
| Related CAS # |
Succinyl phosphonate;26647-82-5
|
| PubChem CID |
138911342
|
| Appearance |
White to light yellow solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
14
|
| Complexity |
225
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Na].O=C(CCC(P(O)(O)=O)=O)O
|
| InChi Key |
QHBOYEUINLIJDF-UHFFFAOYSA-K
|
| InChi Code |
InChI=1S/C4H7O6P.3Na/c5-3(6)1-2-4(7)11(8,9)10;;;/h1-2H2,(H,5,6)(H2,8,9,10);;;/q;3*+1/p-3
|
| Chemical Name |
trisodium;4-oxo-4-phosphonatobutanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~201.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (100.80 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8766 mL | 24.3831 mL | 48.7662 mL | |
| 5 mM | 0.9753 mL | 4.8766 mL | 9.7532 mL | |
| 10 mM | 0.4877 mL | 2.4383 mL | 4.8766 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
